Brief: Rigel Announces Publication Of Final Arrow Clinical Trial Data On Gavreto® (Pralsetinib)
31/03/2026 13:10
March 31 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O: RIGEL ANNOUNCES PUBLICATION OF FINAL ARROW CLINICAL TRIAL DATA ON GAVRETO® (PRALSETINIB) IN PATIENTS WITH RET+ NSCLC IN THE JOURNAL OF CLINICAL ONCOLOGY Source text: ID:nPn9vXr73a Further company coverage: RIGL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)